Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
2026 S3: prohibited at all times; Specified. A conditional inhaled exception applies; all limits and qualifications below matter. [1]
S3; printed p. 9 and relevant S5 note, p. 12 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulations
The US Serevent Diskus label describes salmeterol inhalation powder for selected asthma use with an inhaled corticosteroid, exercise-induced bronchospasm prevention and COPD maintenance. It is not for acute symptom relief. [2]
- Product and jurisdiction specific; this is not an exhaustive brand, indication or route inventory.
Selected health warnings
LABA monotherapy in asthma carries an asthma-related-death warning. The label separately describes evidence for fixed ICS/LABA combinations, so the monotherapy warning must not be assigned unchanged to all combination treatment. [2]
- No treatment dose, device conversion or personal eligibility determination is provided.
Limits of the inhaled exception
The 2026 inhaled exception sets 200 micrograms over 24 hours, in divided doses, and 100 micrograms over any eight-hour interval starting with a dose. A daily-total-only description misses a condition. [1]
- These are anti-doping limits, not recommended or safe medical doses. Other routes, products, combined exposure and TUE requirements need individual review.
Unresolved dose terminology
WADA’s current FAQ describes the salmeterol limit using a metered-inhaler dose, while the 2026 explanatory notes call it a delivered dose. This review preserves the discrepancy rather than supplying a device conversion. [3] [4]
- A clinician and the responsible anti-doping authority should resolve the product-specific interpretation before relying on a calculation.
What remains uncertain
- No exact ordinary-food or supplement-contamination pathway was established by the retained sources; this is a research limitation, not proof of absence.
- Official metered-versus-delivered wording conflict remains unresolved; no device or puff calculator should use this record.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Serevent Diskus salmeterol US label ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
- WADA Prohibited List FAQ ↗Accessed 2026-11-10 · Relevant document text opened
S3/S5 text and relevant FAQ answers
- WADA 2026 explanatory notes ↗Accessed 2026-11-10 · Relevant document text opened
p. 1, S3 and S4 explanatory notes
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.